

# COVID-19 Vaccine

## Interim COVID-19 Immunization Schedule for Ages 5 Years and Older



COVID-19 vaccines are recommended for persons 5 years of age and older within the scope of the Emergency Use Authorization or Biologics License Application for the vaccine. The table below provides guidance for COVID-19 vaccination schedules based on age and medical condition. Considerations when scheduling vaccine doses include:

- Administer the appropriate vaccine product based on the recipient's age and the vaccine product's age indications.
- COVID-19 vaccines may be administered on the same day as other vaccines.
- Doses administered up to 4 days before the minimum interval (4-day grace period) are considered valid. Doses administered at any time after the recommended interval are valid.

Detailed information can be found in CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States (link provided).

**Table 1. Immunization schedule for persons 5 years of age and older**

Type	Recipient Age	Product	Persons Who <b>ARE NOT</b> Moderately or Severely Immunocompromised		Persons Who <b>ARE</b> Moderately or Severely Immunocompromised	
			Primary Series*	Booster Dose†‡	Primary Series*	Booster Dose†‡
mRNA vaccine	5–11 years	Pfizer-BioNTech Ages: 5–11 years Orange cap	2 doses. Separate: Dose 1 and 2 by at least 3 weeks.	Not recommended	3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks.	Not recommended
	12–17 years	Pfizer-BioNTech Ages: 12 years and older Gray cap or Purple cap	2 doses. Separate: Dose 1 and 2 by at least 3 - 8 weeks.§	At least 5 months after Dose 2	3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks.	At least 12 weeks after Dose 3¶
	18 years and older	Pfizer-BioNTech Ages: 12 years and older Gray cap or Purple cap	2 doses. Separate: Dose 1 and 2 by at least 3 - 8 weeks.§	At least 5 months after Dose 2**	3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks.	At least 12 weeks after Dose 3¶
		Moderna	2 doses. Separate: Dose 1 and 2 by at least 4 - 8 weeks.§	At least 5 months after Dose 2**	3 doses. Separate: Dose 1 and 2 by at least 4 weeks. Dose 2 and 3 by at least 4 weeks.	At least 12 weeks after Dose 3¶
Viral vector vaccine	18 years and older	Janssen††	1 dose	At least 8 weeks after Dose 1††	2 doses. Separate: Dose 1 and 2§§ by at least 28 days	At least 8 weeks after Dose 2¶

\* Complete the primary series using the same product. Every effort should be made to determine which vaccine product was received as the first dose. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.

† A different COVID-19 vaccine product than the primary series may be administered for the booster dose. An mRNA COVID-19 vaccine is preferred.

‡ Persons with a recent SARS-CoV-2 infection may consider delaying their first or second COVID-19 vaccine booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

§ An 8-week interval may be optimal for some people, including males 12-39 years of age because of the small risk of myocarditis associated with mRNA COVID-19 vaccines. Vaccine effectiveness may also be increased with an interval longer than 3 or 4 weeks (depending on the product).

¶ Moderately or severely immunocompromised persons may receive a 2nd booster dose at least 4 months after the last dose. Administer an mRNA vaccine only (Moderna or Pfizer-BioNTech COVID-19 Vaccine).

\*\* Persons 50 years of age and older may receive a 2nd mRNA booster dose at least 4 months after the last dose.

†† mRNA COVID-19 vaccines are preferred over the Janssen COVID-19 Vaccine for all vaccine-eligible people. However, the Janssen COVID-19 Vaccine may be offered in some situations.

‡‡ Persons may receive a 2nd booster dose who are:

- 18 years of age and older and received 2 doses of Janssen vaccine. Administer Moderna or Pfizer-BioNTech COVID-19 Vaccine only.
- 50 years of age or older who received a primary dose of Janssen vaccine and a mRNA booster dose. Administer Moderna or Pfizer-BioNTech COVID-19 Vaccine only.

§§ Administer Moderna or Pfizer-BioNTech COVID-19 Vaccine only.

# COVID-19 Vaccine

Interim COVID-19 Immunization Schedule  
for Ages 5 Years and Older



**Table 2. COVID-19 Vaccine Products Summary**

Product	Age Indications	Diluent	Dosage (amount injected)	
Type: mRNA vaccine				
Pfizer-BioNTech Orange cap and bordered label	5 - 11 years	1.3 mL 0.9% sodium chloride (normal saline, preservative-free)	Doses 1 and 2	0.2 mL
			Dose 3*	0.2 mL
			Booster dose	Not recommended
Pfizer-BioNTech Gray cap and bordered label	12 years and older	NONE	Doses 1 and 2	0.3 mL
			Dose 3*	0.3 mL
			Booster dose <sup>†</sup>	0.3 mL
Pfizer-BioNTech Purple cap	12 years and older	1.8 mL 0.9% sodium chloride (normal saline, preservative-free)	Doses 1 and 2	0.3 mL
			Dose 3*	0.3 mL
			Booster dose <sup>†</sup>	0.3 mL
Moderna Red cap	18 years and older	NONE	Doses 1 and 2	0.5 mL
			Dose 3*	0.5 mL
			Booster dose <sup>†</sup>	0.25 mL

Product	Age Indications	Diluent	Dosage (amount injected)	
Type:Viral Vector Vaccine				
Janssen <sup>‡</sup> Blue Cap	18 years and older	NONE	Dose 1	0.5 mL
			Dose 2*	Dose 2 Administer mRNA vaccine only <sup>§</sup>
			Booster dose <sup>†</sup>	0.5 mL

\* For moderate or severely immunocompromised persons only

† Some persons may receive a 2nd booster dose. Administer Moderna or Pfizer-BioNTech COVID-19 Vaccine ONLY. Administer the correct product based on the recipient's age. If administering Moderna COVID-19 Vaccine, administer 0.25 mL. See Table 1 or Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States (link provided) for detailed information.

‡ mRNA vaccines are preferred.

§ Additional dose for moderate or severely immunocompromised persons only: Administer Moderna or Pfizer-BioNTech COVID-19 Vaccine ONLY. Administer the correct product based on the recipient's age. If administering Moderna COVID-19 Vaccine, administer 0.5 mL.

## CDC Resources

CDC COVID-19 Vaccine clinical training and materials at: [www.cdc.gov/vaccines/covid-19/info-by-product/index.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html)

CDC Interim clinical considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States at [www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series)